Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2016 - 2026)

Insight Molecular Diagnostics' Cash & Current Investments history spans 7 years, with the latest figure at $12.3 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 42.57% to $12.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.3 million, a 42.57% increase, with the full-year FY2025 number at $12.3 million, up 42.57% from a year prior.
  • Cash & Current Investments hit $12.3 million in Q4 2025 for Insight Molecular Diagnostics, down from $19.4 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for IMDX hit a ceiling of $59.8 million in Q1 2021 and a floor of $866000.0 in Q4 2022.
  • Historically, Cash & Current Investments has averaged $19.8 million across 5 years, with a median of $15.1 million in 2023.
  • The widest YoY moves for Cash & Current Investments: up 989.15% in 2023, down 97.29% in 2023.
  • Tracing IMDX's Cash & Current Investments over 5 years: stood at $1.8 million in 2021, then tumbled by 52.1% to $866000.0 in 2022, then surged by 989.15% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then skyrocketed by 42.57% to $12.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for IMDX at $12.3 million in Q4 2025, $19.4 million in Q3 2025, and $24.3 million in Q2 2025.